Trial Profile
A Phase II study of capecitabine plus cisplatin (plus trastuzumab) for previously untreated advanced gastric cancer.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Aug 2017
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Cisplatin (Primary) ; Trastuzumab (Primary)
- Indications Gastric cancer
- Focus Therapeutic Use
- 01 Aug 2017 Status changed from recruiting to discontinued.
- 03 Aug 2011 New trial record